These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11959565)

  • 21. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment.
    Melikyan GB; Platt EJ; Kabat D
    Retrovirology; 2007 Aug; 4():55. PubMed ID: 17686153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
    Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
    AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
    Tremblay CL; Giguel F; Guan Y; Chou TC; Takashima K; Hirsch MS
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3483-5. PubMed ID: 16048964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sch-351125 and Sch-350634. Schering-Plough.
    Esté JA
    Curr Opin Investig Drugs; 2002 Mar; 3(3):379-83. PubMed ID: 12054083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 entry and entry inhibitors as therapeutic agents.
    Starr-Spires LD; Collman RG
    Clin Lab Med; 2002 Sep; 22(3):681-701. PubMed ID: 12244592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of HIV antiretroviral drug resistance.
    Chen TK; Aldrovandi GM
    Pediatr Infect Dis J; 2008 Aug; 27(8):749-52. PubMed ID: 18664987
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
    Strizki JM; Tremblay C; Xu S; Wojcik L; Wagner N; Gonsiorek W; Hipkin RW; Chou CC; Pugliese-Sivo C; Xiao Y; Tagat JR; Cox K; Priestley T; Sorota S; Huang W; Hirsch M; Reyes GR; Baroudy BM
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4911-9. PubMed ID: 16304152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.
    Xu W; Wang Q; Yu F; Lu L; Jiang S
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):1-6. PubMed ID: 24977378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.
    Ochsenbauer-Jambor C; Jones J; Heil M; Zammit KP; Kutsch O
    Biotechniques; 2006 Jan; 40(1):91-100. PubMed ID: 16454046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
    Nitanda T; Wang X; Kumamoto H; Haraguchi K; Tanaka H; Cheng YC; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3355-60. PubMed ID: 16048947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
    Moncunill G; Armand-Ugón M; Pauls E; Clotet B; Esté JA
    AIDS; 2008 Jan; 22(1):23-31. PubMed ID: 18090388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.